title: [A case of primary amyloidosis].
abstract: Diagnostics of primary (AL) amyloidosis is difficult enough; treatment of this disease in not less difficult or more adequate. Because of similarity of the pathogenesis of AL-amyloidosis and that of multiple myeloma, similar therapeutic regimens, directed towards depression of plasma cell dyscrasia, are used in both cases: administration of melphalan in various doses together with prednisolone, administration of vincristine, adriablastine and dexamethasone, as well as high-dose chemotherapy with melphalan and autologic stem cell transplantation. This therapeutic approach makes it possible to reach clinico-laboratory remission and prolong the life of patients with AL-amyloidosis. The article contains a case description of a patient with AL-amyloidosis, who underwent a successful high-dose melphalan therapy with subsequent autologic stem cell transplantation.
authors.forename: V N
authors.initials: VN
authors.lastname: Ardashev
authors.forename: N P
authors.initials: NP
authors.lastname: Potekhin
authors.forename: O A
authors.initials: OA
authors.lastname: Rukavitsyn
authors.forename: A G
authors.initials: AG
authors.lastname: Borisov
authors.forename: S A
authors.initials: SA
authors.lastname: Malysheva
mesh_terms: D000686:Amyloidosis / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D008297:Male; D008558:Melphalan / Q000627:therapeutic use*; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007074:Immunoglobulin G; D011239:Prednisolone; D008558:Melphalan